A Study of LY3437943 in Participants With Type 2 Diabetes

NCT04867785 on ClinicalTrials.gov · last registry update 2023-07-03

An unusually large phase 2: 281 participants, more than double the 110 typical for the stage. The sponsor logged completion for 8 July 2022. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c). dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 281
Started: 2021-05-13
Primary completion: 2022-07-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.